Indaptus Therapeutics, Inc. (INDP)
Data as of , from SEC Form 4 filings.
See up to 3 months of INDP. The 7-day demo opens the 1M and 3M ranges and puts INDP on your watchlist.
Start 7-day demoData as of , from SEC Form 4 filings.
See up to 3 months of INDP. The 7-day demo opens the 1M and 3M ranges and puts INDP on your watchlist.
Start 7-day demoIndaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
No Form 4 activity for INDP in the last 90 days.
16 Form 4 filings on record, the earliest from Oct 10, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| David E. Lazar - Director | Open-market sale | Series AAA Convertible Non-Redeemable Preferred Stock | 700,000 | - footnote F1 | - | |
| David E. Lazar - Director | Open-market sale | Series AA Convertible Non-Redeemable Preferred Stock | 196,800 | - footnote F1 | - | |
| ||||||
| Jerome D. Jabbour - Director | Grant or award | Option to Buy Common Stock | 25,000 | $0.00 | - | |
| Jeffrey A. Meckler - Officer | Derivative | Warrants (right to buy) | 3,033 | - footnote F1 | - | |
| Jeffrey A. Meckler - Officer | Grant or award | Warrants (right to buy) | 3,033 | - footnote F1 | - | |
| Jeffrey A. Meckler - Officer | Derivative | Warrants (right to buy) | 1,519 | - footnote F1 | - | |
| Jeffrey A. Meckler - Officer | Grant or award | Warrants (right to buy) | 1,519 | - footnote F1 | - | |
| Jeffrey A. Meckler - Officer | Derivative | Warrants (right to buy) | 12,136 | - footnote F1 | - | |
| Jeffrey A. Meckler - Officer | Grant or award | Warrants (right to buy) | 12,136 | - footnote F1 | - | |
| ||||||
| Avraham Ben-Tzvi - Director | Grant or award | Common Stock | 25,000 | $0.00 footnote F1 | - | |
| Avraham Ben-Tzvi - Director | Grant or award | Option to Buy Common Stock | 25,000 | $0.00 footnote F3 | - | |
| ||||||
| David Natan - Director | Grant or award | Option to Buy Common Stock | 25,000 | $0.00 | - | |
| Nir Sassi - Officer | Grant or award | Common Stock | 26,758 footnote F1 | $2.03 | $54K | |
| ||||||
| Jeffrey A. Meckler - Officer | Grant or award | Common Stock | 216,617 footnote F1 | $2.03 | $440K | |
| ||||||
| Michael James Newman - Officer | Grant or award | Common Stock | 52,204 footnote F1 | $2.03 | $106K | |
| ||||||
| Walt Addison Linscott - Officer | Grant or award | Common Stock | 54,421 footnote F1 | $2.03 | $110K | |
| ||||||
| Jeffrey A. Meckler - Officer | Grant or award | Common Stock | 6,068 | $8.30 | $50K | |
| Jeffrey A. Meckler - Officer | Grant or award | Common Stock Warrants | 12,136 | $8.30 | $101K | |
| Jeffrey A. Meckler - Officer | Grant or award | Common stock | 42,553 | $32.90 | $50K | |
| Jeffrey A. Meckler - Officer | Grant or award | Common Stock Warrants | 42,553 | $32.90 | $50K | |
| Michael James Newman - Officer | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Nir Sassi - Officer | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Roger J. Waltzman - Officer | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Walt Addison Linscott - Officer | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Jeffrey A. Meckler - Officer | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
Indaptus Therapeutics, Inc. (INDP) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-03-24. The full record for INDP runs to 16 Form 4 filings, the earliest from 2024-10-10. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
No insider purchases of INDP were filed in the last 90 days.
No insider sales of INDP were filed in the last 90 days. 2 sales are on record for this company.
This page collects INDP Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
